These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32827442)

  • 21. A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes.
    Hoffman KB; Dimbil M; Kyle RF; Tatonetti NP; Erdman CB; Demakas A; Chen D; Overstreet BM
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1134-43. PubMed ID: 26679963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comment on 'empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership'.
    Gagne JJ; Schneeweiss S
    Stat Med; 2013 Mar; 32(6):1073-4. PubMed ID: 23413214
    [No Abstract]   [Full Text] [Related]  

  • 23. A review of risk measures in pharmacoepidemiology with tips for statisticians in the pharmaceutical industry.
    Quartey G; Wang J; Kim J
    Pharm Stat; 2011; 10(6):548-53. PubMed ID: 22127819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacoepidemiology and its input to pharmacovigilance.
    Faillie JL; Montastruc F; Montastruc JL; Pariente A
    Therapie; 2016 Apr; 71(2):211-6. PubMed ID: 27080840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systems pharmacology augments drug safety surveillance.
    Lorberbaum T; Nasir M; Keiser MJ; Vilar S; Hripcsak G; Tatonetti NP
    Clin Pharmacol Ther; 2015 Feb; 97(2):151-8. PubMed ID: 25670520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving pediatric drug safety: need for more efficient clinical translation of pharmacovigilance knowledge.
    Castro-Pastrana LI; Carleton BC
    J Popul Ther Clin Pharmacol; 2011; 18():e76-88. PubMed ID: 21467599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug safety, pharmacoepidemiology, and regulatory decision making.
    Nelson RC
    Drug Intell Clin Pharm; 1988 Apr; 22(4):336-44. PubMed ID: 3371198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolving paradigms in pharmacovigilance.
    Brewster W; Gibbs T; Lacroix K; Murray A; Tydeman M; Almenoff J
    Curr Drug Saf; 2006 May; 1(2):127-34. PubMed ID: 18690923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods.
    Montastruc JL; Sommet A; Lacroix I; Olivier P; Durrieu G; Damase-Michel C; Lapeyre-Mestre M; Bagheri H
    Joint Bone Spine; 2006 Dec; 73(6):629-32. PubMed ID: 17110152
    [No Abstract]   [Full Text] [Related]  

  • 30. Some observations on pharmacoepidemiology in Europe.
    van Boxtel CJ; Wang G
    Neth J Med; 1997 Dec; 51(6):205-12. PubMed ID: 9499691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to comment on 'empirical assessment of methods for risk identification in healthcare data'.
    Ryan PB; Madigan D; Stang PE; Marc Overhage J; Racoosin JA; Hartzema AG
    Stat Med; 2013 Mar; 32(6):1075-7. PubMed ID: 23413215
    [No Abstract]   [Full Text] [Related]  

  • 32. Evaluation of Electronic Healthcare Databases for Post-Marketing Drug Safety Surveillance and Pharmacoepidemiology in China.
    Yang Y; Zhou X; Gao S; Lin H; Xie Y; Feng Y; Huang K; Zhan S
    Drug Saf; 2018 Jan; 41(1):125-137. PubMed ID: 28815480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacoepidemiology in practice. Current status and future trends.
    Alvarez-Requejo A; Porta M
    Drug Saf; 1995 Jul; 13(1):1-7. PubMed ID: 8527015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacoeconomics and pharmacoepidemiology: curious bedfellows or a match made in heaven?
    Briggs AH; Levy AR
    Pharmacoeconomics; 2006; 24(11):1079-86. PubMed ID: 17067193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacoepidemiology.
    Moore N; Blin P; Droz C
    Handb Exp Pharmacol; 2019; 260():433-451. PubMed ID: 31768750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Erice Manifesto: for global reform of the safety of medicines in patient care.
    Drug Saf; 2007; 30(3):187-90. PubMed ID: 17343426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacoepidemiology, the new paradigm of drug evaluation.
    Bégaud B; Montastruc JL
    Therapie; 2019 Apr; 74(2):167-168. PubMed ID: 30686638
    [No Abstract]   [Full Text] [Related]  

  • 38. Challenges and opportunities for pharmacoepidemiology in drug-therapy decision making.
    Etminan M; Gill S; Fitzgerald M; Samii A
    J Clin Pharmacol; 2006 Jan; 46(1):6-9. PubMed ID: 16397278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacoepidemiology--its relevance to clinical practice.
    Hartzema AG
    J Clin Pharm Ther; 1992 Apr; 17(2):73-4. PubMed ID: 1583081
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacoepidemiology.
    Inman WHW
    Br Med J (Clin Res Ed); 1984 Nov; 289(6456):1450-1. PubMed ID: 6437592
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.